Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
IDIX's Cash to Debt is ranked higher than
84% of the 902 Companies
in the Global Biotechnology industry.

( Industry Median: 83.08 vs. IDIX: No Debt )
IDIX' s 10-Year Cash to Debt Range
Min: 2.47   Max: No Debt
Current: No Debt

Equity to Asset 0.83
IDIX's Equity to Asset is ranked higher than
85% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. IDIX: 0.83 )
IDIX' s 10-Year Equity to Asset Range
Min: -0.74   Max: 0.88
Current: 0.83

-0.74
0.88
Interest Coverage No Debt
IDIX's Interest Coverage is ranked higher than
98% of the 408 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. IDIX: No Debt )
IDIX' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

F-Score: 4
Z-Score: 50.60
M-Score: 48.58
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -26379.53
IDIX's Operating margin (%) is ranked lower than
52% of the 790 Companies
in the Global Biotechnology industry.

( Industry Median: -71.36 vs. IDIX: -26379.53 )
IDIX' s 10-Year Operating margin (%) Range
Min: -26379.53   Max: -8.59
Current: -26379.53

-26379.53
-8.59
Net-margin (%) -26073.99
IDIX's Net-margin (%) is ranked lower than
52% of the 790 Companies
in the Global Biotechnology industry.

( Industry Median: -59.60 vs. IDIX: -26073.99 )
IDIX' s 10-Year Net-margin (%) Range
Min: -26073.99   Max: -6.55
Current: -26073.99

-26073.99
-6.55
ROE (%) -115.37
IDIX's ROE (%) is ranked higher than
54% of the 812 Companies
in the Global Biotechnology industry.

( Industry Median: -20.84 vs. IDIX: -115.37 )
IDIX' s 10-Year ROE (%) Range
Min: -954.79   Max: -5.73
Current: -115.37

-954.79
-5.73
ROA (%) -86.72
IDIX's ROA (%) is ranked higher than
54% of the 890 Companies
in the Global Biotechnology industry.

( Industry Median: -17.36 vs. IDIX: -86.72 )
IDIX' s 10-Year ROA (%) Range
Min: -313.72   Max: -3.34
Current: -86.72

-313.72
-3.34
ROC (Joel Greenblatt) (%) -4447.16
IDIX's ROC (Joel Greenblatt) (%) is ranked higher than
55% of the 862 Companies
in the Global Biotechnology industry.

( Industry Median: -247.50 vs. IDIX: -4447.16 )
IDIX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -4447.16   Max: -120.4
Current: -4447.16

-4447.16
-120.4
Revenue Growth (%) -100.00
IDIX's Revenue Growth (%) is ranked higher than
52% of the 624 Companies
in the Global Biotechnology industry.

( Industry Median: -1.80 vs. IDIX: -100.00 )
IDIX' s 10-Year Revenue Growth (%) Range
Min: -100   Max: 235.2
Current: -100

-100
235.2
EBITDA Growth (%) 0.70
IDIX's EBITDA Growth (%) is ranked higher than
81% of the 598 Companies
in the Global Biotechnology industry.

( Industry Median: -10.50 vs. IDIX: 0.70 )
IDIX' s 10-Year EBITDA Growth (%) Range
Min: -69.4   Max: 105.7
Current: 0.7

-69.4
105.7
EPS Growth (%) 1.50
IDIX's EPS Growth (%) is ranked higher than
83% of the 631 Companies
in the Global Biotechnology industry.

( Industry Median: -12.60 vs. IDIX: 1.50 )
IDIX' s 10-Year EPS Growth (%) Range
Min: -77.4   Max: 114
Current: 1.5

-77.4
114
» IDIX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2013

IDIX Guru Trades in Q2 2013

Chuck Royce 736,000 sh (New)
Jeremy Grantham 29,600 sh (+69.14%)
Seth Klarman 26,767,000 sh (+2.78%)
Jim Simons 16,466 sh (-97.14%)
» More
Q3 2013

IDIX Guru Trades in Q3 2013

Seth Klarman 29,665,693 sh (+10.83%)
Chuck Royce 736,000 sh (unchged)
Jim Simons Sold Out
Jeremy Grantham 21,600 sh (-27.03%)
» More
Q4 2013

IDIX Guru Trades in Q4 2013

Steven Cohen 13,900 sh (New)
Jeremy Grantham 56,100 sh (+159.72%)
Seth Klarman 36,910,868 sh (+24.42%)
Chuck Royce 665,980 sh (-9.51%)
» More
Q1 2014

IDIX Guru Trades in Q1 2014

Steven Cohen 96,000 sh (+590.65%)
Seth Klarman 53,331,109 sh (+44.49%)
Jeremy Grantham Sold Out
Chuck Royce 534,316 sh (-19.77%)
» More
» Details

Insider Trades

Latest Guru Trades with IDIX

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Seth Klarman 2014-03-31 Add 44.49%2.25%$5.82 - $8.04 $ 24.32249%53331109
Seth Klarman 2013-12-31 Add 24.42%1.24%$3.29 - $6.93 $ 24.32429%36910868
Seth Klarman 2013-09-30 Add 10.83%0.43%$3.22 - $5.75 $ 24.32455%29665693
Seth Klarman 2013-03-31 Add 25.78%0.61%$3.54 - $5.36 $ 24.32429%26042000
John Burbank 2013-03-31 Sold Out 0.19%$3.54 - $5.36 $ 24.32429%0
Seth Klarman 2012-12-31 Add 72.54%1.35%$3.52 - $5.3 $ 24.32439%20704700
Jean-Marie Eveillard 2012-12-31 Sold Out 0.0025%$3.52 - $5.3 $ 24.32439%0
Seth Klarman 2012-09-30 Add 20%0.28%$4.39 - $11.06 $ 24.32208%12000000
Jean-Marie Eveillard 2012-09-30 New Buy$4.39 - $11.06 $ 24.32208%150000
Seth Klarman 2012-06-30 Add 21.23%0.47%$7.24 - $10.71 $ 24.32173%10000000
John Burbank 2012-06-30 Add 150%0.26%$7.24 - $10.71 $ 24.32173%1250000
Seth Klarman 2012-03-31 Add 45.61%0.85%$7.01 - $14.89 $ 24.32121%8249000
John Burbank 2012-03-31 New Buy0.17%$7.01 - $14.89 $ 24.32121%500000
George Soros 2012-03-31 Sold Out 0.08%$7.01 - $14.89 $ 24.32121%0
Seth Klarman 2011-12-31 Add 126.6%0.73%$4.55 - $8.22 $ 24.32275%5665000
George Soros 2011-12-31 Add 1382.72%0.08%$4.55 - $8.22 $ 24.32275%255028
Seth Klarman 2011-09-30 Add 99.09%0.21%$4.15 - $6.96 $ 24.32328%2500000
George Soros 2011-09-30 New Buy$4.15 - $6.96 $ 24.32328%17200
Seth Klarman 2011-06-30 New Buy0.26%$2.9 - $5.3 $ 24.32423%1255700
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about Idenix Pharmaceuticals Inc

Seth Klarman Is Top-Performing Guru for First Half 2014
After making a $1 billion gain on Idenix Pharmaceuticals Inc. (IDIX) and his stock picks of the past six months on average gaining 60.8% in the first half of the year compared to about 6% for the S&P 500, Seth Karman resoundingly leads GuruFocus’ scoreboard. Read more...
Seth Klarman Buys Cheniere Energy, Keryx Biopharmaceuticals, Idenix Pharmaceuticals, Sells BP, Fidelity National Financial
The Baupost Group, the hedge fund firm run by famed investor Seth Klarman (Trades, Portfolio), just reported their first quarter portfolio. Seth Klarman (Trades, Portfolio) buys Cheniere Energy Inc, Keryx Biopharmaceuticals Inc, Idenix Pharmaceuticals Inc, PBF Energy Inc, RF Micro Devices Inc, Triquint Semiconductor, Viasat Inc, Theravance Inc, Keryx Biopharmaceuticals Inc, sells BP PLC, Fidelity National Financial Inc, Rovi Corp, Enzon Pharmaceuticals Inc during the 3-months ended 03/31/2014, according to the most recent filings of his investment company, The Baupost Group. As of 03/31/2014, The Baupost Group owns 20 stocks with a total value of $4.1 billion. These are the details of the buys and sells.
New Purchases: LNG, KERX, RFMD, TQNT, KERX, Added Positions: IDIX, PBF, VSAT, THRX, Reduced Positions: BP, Sold Out: FNF, ROVI, ENZN, For the details of Seth Klarman (Trades, Portfolio)'s stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=Seth+Klarman
This is the sector weightings of his portfolio:

Technology

52.8%

Healthcare

26.7%

Energy

11.4%

Basic Materials

2.1%

Consumer Defensive

0.4%

These are the top 5 holdings of Seth Klarman (Trades, Portfolio)

1. Micron Technology Inc (MU) - 51,655,434 shares, 29.5% of the total portfolio.
2. Viasat Inc (VSAT) - 11,395,900 shares, 19.0% of the total portfolio. Shares added by 2.4%
3. Theravance Inc (THRX) - 20,705,801 shares, 15.5% of the total portfolio. Shares added by 2.79%
4. Cheniere Energy Inc (LNG) - 5,660,000 shares, 7.6% of the total portfolio. New Position
5. Idenix Pharmaceuticals Inc (IDIX) - 53,331,109 shares, 7.3% of the total portfolio. Shares added by 44.49%

New Purchase: Cheniere Energy Inc (LNG)
Seth Klarman (Trades, Portfolio) initiated holdings in Cheniere Energy Inc. His purchase prices were between $40.88 and $54.87, with an estimated average price of $47.65. The impact to his portfolio due to this purchase was 7.6%. His holdings were 5,660,000 shares as of 03/31/2014. Cheniere Energy Inc, a Delaware corporation, is a Houston-based energy company primarily engaged in LNG-related businesses. Cheniere Energy Inc has a market cap of $13.56 billion; its shares were traded at around $56.98 with and P/S ratio of 46.80.

New Purchase: Keryx Biopharmaceuticals Inc (KERX)
Seth Klarman (Trades, Portfolio) initiated holdings in Keryx Biopharmaceuticals Inc. His purchase prices were between $12.16 and $16.88, with an estimated average price of $14.98. The impact to his portfolio due to this purchase was 2.6%. His holdings were 6,310,850 shares as of 03/31/2014. Keryx Biopharmaceuticals, Inc is a Delaware corporation incorporated in Delaware in October 1998. Keryx Biopharmaceuticals Inc has a market cap of $1.17 billion; its shares were traded at around $12.79 with and P/S ratio of 107.10.

New Purchase: RF Micro Devices Inc (RFMD)
Seth Klarman (Trades, Portfolio) initiated holdings in RF Micro Devices Inc. His purchase prices were between $4.51 and $7.93, with an estimated average price of $6.09. The impact to his portfolio due to this purchase was 1.3%. His holdings were 6,585,000 shares as of 03/31/2014. RF Micro Devices, Inc. was incorporated under the laws of the State of North Carolina in 1991. Rf Micro Devices Inc has a market cap of $2.46 billion; its shares were traded at around $8.72 with and P/S ratio of 2.10.

New Purchase: Triquint Semiconductor (TQNT)
Seth Klarman (Trades, Portfolio) initiated holdings in Triquint Semiconductor. His purchase prices were between $8.07 and $13.55, with an estimated average price of $10.28. The impact to his portfolio due to this purchase was 1.2%. His holdings were 3,825,000 shares as of 03/31/2014. Triquint Semiconductor was incorporated in California in 1981 and reincorporated in Delaware on February 12, 1997. Triquint Semiconductor has a market cap of $2.49 billion; its shares were traded at around $14.51 with and P/S ratio of 2.60. Triquint Semiconductor had an annual average earnings growth of 11.00% over the past 10 years.

New Purchase: Keryx Biopharmaceuticals Inc (KERX)
Seth Klarman (Trades, Portfolio) initiated holdings in Keryx Biopharmaceuticals Inc. The impact to his portfolio due to this purchase was 3.11%. His holdings were 9,151,600 shares as of 03/31/2014. Keryx Biopharmaceuticals, Inc is a Delaware corporation incorporated in Delaware in October 1998. Keryx Biopharmaceuticals Inc has a market cap of $1.17 billion; its shares were traded at around $12.79 with and P/S ratio of 107.10.

Sold Out: Fidelity National Financial Inc (FNF)
Seth Klarman (Trades, Portfolio) sold out his holdings in Fidelity National Financial Inc. His sale prices were between $29.78 and $33.22, with an estimated average price of $31.66. Fidelity National Financial, Inc. was incorporated in the State of Delaware. Fidelity National Financial Inc has a market cap of $9.32 billion; its shares were traded at around $33.66 with a P/E ratio of 19.30 and P/S ratio of 1.00. The dividend yield of Fidelity National Financial Inc stocks is 2.00%. Fidelity National Financial Inc had an annual average earnings growth of 17.60% over the past 5 years.

Sold Out: Rovi Corp (ROVI)
Seth Klarman (Trades, Portfolio) sold out his holdings in Rovi Corp. His sale prices were between $19.38 and $25.2, with an estimated average price of $22.8. Rovi Corp, a Delaware corporation was formed in 2007. Rovi Corp has a market cap of $2.18 billion; its shares were traded at around $23.00 with and P/S ratio of 4.20. Rovi Corp had an annual average earnings growth of 5.80% over the past 10 years. GuruFocus rated Rovi Corp the business predictability rank of 3.5-star.

Sold Out: Enzon Pharmaceuticals Inc (ENZN)
Seth Klarman (Trades, Portfolio) sold out his holdings in Enzon Pharmaceuticals Inc. His sale prices were between $0.861 and $1.26, with an estimated average price of $1.04. Enzon Pharmaceuticals, Inc., a biotechnology company, was founded on 1981. Enzon Pharmaceuticals Inc has a market cap of $40.100 million; its shares were traded at around $0.91 with a P/E ratio of 2.30 and P/S ratio of 1.40.

Added: Idenix Pharmaceuticals Inc (IDIX)
Seth Klarman (Trades, Portfolio) added to his holdings in Idenix Pharmaceuticals Inc by 44.49%. His purchase prices were between $5.82 and $8.04, with an estimated average price of $6.96. The impact to his portfolio due to this purchase was 2.25%. His holdings were 53,331,109 shares as of 03/31/2014. Idenix Pharmaceuticals, Inc. is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases with operations in the United States and Europe. Idenix Pharmaceuticals Inc has a market cap of $859.800 million; its shares were traded at around $5.70 .

Added: PBF Energy Inc (PBF)
Seth Klarman (Trades, Portfolio) added to his holdings in PBF Energy Inc by 174.04%. His purchase prices were between $23.79 and $31.46, with an estimated average price of $26.73. The impact to his portfolio due to this purchase was 2.16%. His holdings were 5,416,606 shares as of 03/31/2014. PBF Energy Inc is a Delaware corporation incorporated on November 7, 2011. Pbf Energy Inc has a market cap of $2.91 billion; its shares were traded at around $30.06 with a P/E ratio of 22.10 and P/S ratio of 0.10. The dividend yield of Pbf Energy Inc stocks is 4.00%.

Added: Viasat Inc (VSAT)
Seth Klarman (Trades, Portfolio) added to his holdings in Viasat Inc by 2.4%. His purchase prices were between $56.04 and $73.62, with an estimated average price of $64.86. The impact to his portfolio due to this purchase was 0.45%. His holdings were 11,395,900 shares as of 03/31/2014. Viasat Inc was incorporated in California in 1986, and subsequently reincorporated in Delaware in 1996. Viasat Inc has a market cap of $2.72 billion; its shares were traded at around $58.99 with and P/S ratio of 2.00. Viasat Inc had an annual average earnings growth of 9.20% over the past 10 years.

Added: Theravance Inc (THRX)
Seth Klarman (Trades, Portfolio) added to his holdings in Theravance Inc by 2.79%. His purchase prices were between $30.17 and $40.49, with an estimated average price of $36.39. The impact to his portfolio due to this purchase was 0.42%. His holdings were 20,705,801 shares as of 03/31/2014. Theravance Inc., was incorporated in Delaware in November 1996 under the name Advanced Medicine, Inc, and began operations in May 1997. Theravance Inc has a market cap of $3.2 billion; its shares were traded at around $28.37 with and P/S ratio of 819.10.

Reduced: BP PLC (BP)
Seth Klarman (Trades, Portfolio) reduced to his holdings in BP PLC by 44.12%. His sale prices were between $46.04 and $50.67, with an estimated average price of $48.22. The impact to his portfolio due to this sale was -3.44%. Seth Klarman (Trades, Portfolio) still held 3,166,413 shares as of 03/31/2014. BP PLC operates as an integrated oil and gas company and is the parent company of the BP group of companies. Bp Plc has a market cap of $173.49 billion; its shares were traded at around $50.96 with a P/E ratio of 15.80 and P/S ratio of 0.40. The dividend yield of Bp Plc stocks is 4.50%. Bp Plc had an annual average earnings growth of 20.60% over the past 5 years. Read more...
Seth Klarman Amasses a Third of Drug Company, George Soros Adds Mercury Systems
Two well-known gurus, George Soros and Seth Klarman, bought additional shares of companies of which they own more than 5%, according to GuruFocus Real Time Picks. Klarman, leader of the Baupost Group, added shares to his position in Idenix Pharmaceuticals (IDIX), and Soros grew his position in Mercury Systems (MRCY). Read more...

Ratios

vs
industry
vs
history
P/B 20.00
IDIX's P/B is ranked higher than
57% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 5.80 vs. IDIX: 20.00 )
IDIX' s 10-Year P/B Range
Min: 1.28   Max: 74.22
Current: 20

1.28
74.22
EV-to-EBIT -27.28
IDIX's EV-to-EBIT is ranked higher than
66% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. IDIX: -27.28 )
IDIX' s 10-Year EV-to-EBIT Range
Min: 63.5   Max: 96.8
Current: -27.28

63.5
96.8
Current Ratio 9.66
IDIX's Current Ratio is ranked higher than
88% of the 894 Companies
in the Global Biotechnology industry.

( Industry Median: 4.02 vs. IDIX: 9.66 )
IDIX' s 10-Year Current Ratio Range
Min: 1.75   Max: 17.46
Current: 9.66

1.75
17.46
Quick Ratio 9.66
IDIX's Quick Ratio is ranked higher than
89% of the 894 Companies
in the Global Biotechnology industry.

( Industry Median: 3.76 vs. IDIX: 9.66 )
IDIX' s 10-Year Quick Ratio Range
Min: 1.75   Max: 17.46
Current: 9.66

1.75
17.46

Valuation & Return

vs
industry
vs
history
Price/Net Cash 22.10
IDIX's Price/Net Cash is ranked higher than
76% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 63.00 vs. IDIX: 22.10 )
IDIX' s 10-Year Price/Net Cash Range
Min: 2.78   Max: 343
Current: 22.1

2.78
343
Price/Net Current Asset Value 21.90
IDIX's Price/Net Current Asset Value is ranked higher than
75% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 43.44 vs. IDIX: 21.90 )
IDIX' s 10-Year Price/Net Current Asset Value Range
Min: 2.78   Max: 83.67
Current: 21.9

2.78
83.67
Price/Tangible Book 19.90
IDIX's Price/Tangible Book is ranked higher than
61% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 8.86 vs. IDIX: 19.90 )
IDIX' s 10-Year Price/Tangible Book Range
Min: 1.84   Max: 38.05
Current: 19.9

1.84
38.05
Forward Rate of Return (Yacktman) -10.60
IDIX's Forward Rate of Return (Yacktman) is ranked higher than
75% of the 740 Companies
in the Global Biotechnology industry.

( Industry Median: -10.93 vs. IDIX: -10.60 )
IDIX' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -50.3   Max: -32
Current: -10.6

-50.3
-32

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:NO9.Germany
Idenix Pharmaceuticals, Inc. is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases with operations in the United States and Europe. The Company's main research and development focus is on the treatment of hepatitis C virus, or HCV. HCV is a cause of liver disease. The Company is currently developing nucleoside/nucleotide polymerase inhibitors and NS5A inhibitors to inhibit HCV replication. The Company has developed a non-nucleoside reverse transcriptase inhibitor, or NNRTI, drug candidate, IDX899, for the treatment of human immunodeficiency virus type-1, or HIV, and acquired immune deficiency syndrome, or AIDS, for use in combination therapy. In 2008, it successfully completed a proof-of-concept clinical trial of IDX899 in treatment-naïve HIV-infected patients. In February 2009, it licensed its NNRTI compounds to GlaxoSmithKline. In collaboration with Novartis, it developed telbivudine (Tyzeka/Sebivo) through commercialization for the treatment of patients with HBV. In October 2006, the FDA approved Tyzeka in the United States and Sebivo was approved in 2007 in more than 50 countries outside the United States, including major Asian countries and several countries included in the European Union. Companies the compete with in the HCV market include Abbott Laboratories, Boehringer Ingelheim International GmbH, F. Hoffman-LaRoche & Co., Johnson & Johnson, Merck & Co., Inc., Bristol-Myers Squibb Company, Novartis, Gilead Sciences, Inc., Vertex Pharmaceuticals, Inc., Achillion Pharmaceuticals, Inc., Enanta Pharmaceuticals, Inc., and Presidio Pharmaceuticals, Inc. The Company is subject to federal, state and local laws and regulations governing the use, manufacture, storage, handling and disposing of hazardous materials and waste products, including certain regulations promulgated by the U.S. Environmental Protection Agency, or EPA.
» More Articles for IDIX

Headlines

Articles On GuruFocus.com
Seth Klarman Tops Guru Scoreboard for First Half 2014 Jul 05 2014 
The Peril of Being a Copycat Jun 26 2014 
Seth Klarman Buys Cheniere Energy, Keryx Biopharmaceuticals, Idenix Pharmaceuticals, Sells BP, Fidel May 15 2014 
Baupost’s Seth Klarman Takes 10% Stake in Keryx Biopharmaceuticals May 12 2014 
2013 - Mistakes of Commission,Omission & Confusion Feb 12 2014 
Seth Klarman Buys Micron Technology, Theravance, PBF Energy, Sells BP, AIG, Yamana Gold Nov 13 2013 
Seth Klarman Continues Aggressively Buying Drug Company, Soros Adds Mercury Systems Nov 05 2013 
The Philosophy and Value of Gurufocus Sep 08 2013 
Seth Klarman Buys BP, AIG, Elan Corp, Sells News Corp., Oracle May 14 2013 
valuation May 12 2013 


More From Other Websites
Merck, Pfizer Ramping R&D After Q2 Earnings Beat Jul 29 2014
Merck 2Q profit more than doubles Jul 29 2014
Hepatitis C researchers battle to 'nuke' the competition Jul 27 2014
Every Which Way But Short Jul 24 2014
[video] Cramer's Stop Trading: Yellen effect Jul 16 2014
A Pre-Earnings Update On Gilead Jul 10 2014
Seth Klarman Is Top-Performing Guru for First Half 2014 Jul 05 2014
A Primer On The Hepatitis C Market Jul 03 2014
Exclusive: Enanta Pharmaceuticals CEO Jay Luly Discusses Hep C Pipeline Jul 03 2014
Idenix (IDIX) is in Overbought Territory: What's Next? Jul 03 2014
What If Legacy Pharmaceutical And Consumer Business Keeps Falling For Merck? Jun 27 2014
Exclusive: Hepatitis C Stock Valuation With Enanta CEO Jay Luly Jun 27 2014
Keryx Biopharmaceuticals: Baupost Group's New Position Suggests A Possible Takeout And 100%+ Gains Jun 24 2014
Market Wrap For June 20: Yet Again, Dow And S&P 500 Indices Hit New Highs Jun 20 2014
[video] 3 Reasons for Russell 2000 surge Jun 20 2014
Achillion Could Win Idenix's Mystery Suitor: Analyst Jun 20 2014
Speculators On The Next HCV Acquisition Should Not Overlook Technological Platforms Jun 20 2014
Idenix received bid above $18.00 per share prior to deal with Merck Jun 20 2014
Merck begins tender offer to acquire Idenix Jun 20 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

Bradlewski
ReplyBradlewski - 3 weeks ago
Merck is buying it for $24.5/share.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide